Valuation : Natera, Inc.

Market Cap 46.87B 40.33B 37.84B 34.62B 64.62B 4,431B 65.14B 448B 174B 2,264B 176B 172B 7,292B P/E 2026 *
-237x
P/E 2027 * -37,810x
Enterprise Value 45.8B 39.41B 36.98B 33.84B 63.15B 4,330B 63.65B 437B 170B 2,213B 172B 168B 7,126B EV / Sales 2026 *
15.8x
EV / Sales 2027 * 13.1x
Free-Float
97.11%
Yield 2026 *
-
Yield 2027 * -
1 day-0.09%
1 week-4.14%
Current month+0.84%
1 month+20.09%
3 months+53.26%
6 months+56.82%
Current year+41.73%
1 week 316
Extreme 316
339.3
1 month 263.55
Extreme 263.55
343.18
Current year 181
Extreme 181
343.18
1 year 157.42
Extreme 157.425
343.18
3 years 36.9
Extreme 36.9
343.18
5 years 26.1
Extreme 26.1
343.18
10 years 7.35
Extreme 7.35
343.18
Manager TitleAgeSince
Chief Executive Officer 47 02/01/2019
President 46 01/09/2023
Director of Finance/CFO 45 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 47 02/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 A Sell

Founder

-6,000 0.0042%
8/10/26 A Sell

Chairperson

-6,517 0.0046%
8/7/26 A Sell

Founder

-2,000 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
-0.11%-4.14%+93.80%+446.32% 46.87B
-0.36%-1.58%+20.96%+62.01% 26.9B
+3.04%-3.79%-18.74%-40.06% 6.64B
-2.58%-2.48%+3.58%+136.01% 5.96B
+0.47%-0.58%+15.36%+77.39% 3.39B
+0.62%-2.49%-31.60%+1,891.30% 2.59B
+0.14%-6.38%+113.06%+22.97% 2.24B
+6.85%+6.46%+29.55%+35.16% 2.09B
-2.60%-5.64%-13.69%-55.31% 1.83B
-0.73%-6.88%+2.43%-21.84% 1.62B
Average +0.47%-2.01%+21.47%+255.40% 10.01B
Weighted average by Cap. +0.03%-3.25%+51.15%+282.38%

Financials

2026 *2027 *
Net sales 2.91B 2.5B 2.35B 2.15B 4.01B 275B 4.04B 27.75B 10.81B 140B 10.91B 10.67B 452B 3.48B 2.99B 2.81B 2.57B 4.8B 329B 4.84B 33.24B 12.95B 168B 13.07B 12.78B 541B
Net income -193M -166M -156M -143M -266M -18.24B -268M -1.84B -718M -9.32B -725M -709M -30.02B 9.13M 7.85M 7.37M 6.74M 12.59M 863M 12.69M 87.19M 33.95M 441M 34.28M 33.53M 1.42B
Net Debt -1.07B -919M -862M -789M -1.47B -101B -1.48B -10.2B -3.97B -51.6B -4.01B -3.92B -166B -1.36B -1.17B -1.1B -1.01B -1.88B -129B -1.89B -13.02B -5.07B -65.85B -5.12B -5.01B -212B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
03/09/26 $324.72 -0.14% 334,690
02/09/26 $325.17 +1.37% 1,033,232
01/09/26 $320.76 -0.37% 1,208,845
31/08/26 $321.96 -1.32% 1,326,118
28/08/26 $326.26 -3.67% 833,869
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
325.16USD
Average target price
338.07USD
Spread / Average Target
+3.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock